Mabtas 100mg

Mabtas 100mg is a genetically engineered chimeric murine/human monoclonal IgG1 kappa antibody directed against the CD20 antigen. Mabtas has an approximate molecular weight of 145 kD. Mabtas has a binding affinity for the CD20 antigen of approximately 8.0 nm.
Mabtas is produced by mammalian cell (Chinese Hamster Ovary) suspension culture in a nutrient medium that may contain the antibiotic gentamicin.

Gentamicin is not detectable in the final product.
Mabtas 100mg is an anticancer medicine which prevents the growth and spread of cancer cells in the body.
Mabtas 100mg with steroid regimen combination is given for the treatment of some rare disorders which cause blood vessels and other tissues inflammation in the body.

Rituximab

Mabtas

100mg

Intas

Mabtas 100mg indicated for

Mabtas 100mg and hyaluronidase human injection are used as alone or concomitant use with other drugs to treat some types of non-Hodgkin's lymphoma and chronic lymphocytic leukemia (cancer start in WBC).

Mabtas 100mg injection concomitant use with methotrexate (Otrexup, Rasuvo, Xatmep, others) is also used for the treatment rheumatoid arthritis symptoms in adults that have been already treated with some type of drug knowns as tumor necrosis factor (TNF) inhibitor.
Mabtas 100mg is a type in a classification of drugs called monoclonal antibodies.

Mabtas 100mg is indicated to killing cancer cells to treat NHL, CLL, rheumatoid arthritis, granulomatosis with polyangiitis, and microscopic polyangiitis by preventing the activity of the immune system parts which can injury the joints, veins, and other blood vessels and cause organs (heart and lungs) damage.

Mechanism of action

Rituximab is belonging to a classification monoclonal antibody which aim the CD20 antigen declare on the surface of pre-B and mature B-lymphocytes. Upon connecting to CD20, rituximab intercedes B-cell lysis.

B cells are believed to play a role in the pathogenesis of rheumatoid arthritis (RA) and analog to chronic synovitis.

In this setting, B cells may be action at multiple sites in the autoimmune/inflammatory process, involving through production of rheumatoid factor (RF) and other autoantibodies, antigen presentation, T-cell activation, and/or proinflammatory cytokine production.

Dosage and administration

Mabtas injection is generally used to given only via intravenous infusion not by IV push or bolus.
Prior to Each Infusion the Drug Is Premedicate
First infusion:
Initial treatment rate of 50 mg/hr is administer, in not showing infusion toxicity, rate increased up to 50 mg/hr. increments at intervals of 30 min and max of 400 mg/hr.

Successive infusion:
starting at rate of 100 mg/hr., in not showing infusion toxicity, rate increased up to 100 mg/hr. increments at intervals of 30 min and max of 400 mg/hr.
While consolidation with CHOP chemotherapy the injection Mabtas has not been given. Hence Premedication with corticosteroids must be considered.

CHRONIC LYMPHOCYTIC LEUKEMIA

Prior to starting of FC chemotherapy, dose usual given is 375 mg/m2 followed 500 mg/m2 on day 1 of 2-6 cycles every 28 days.

RHEUMATOID ARTHRITIS

When combination of Mabtas injection with methotrexate is administrated.
Mabtas injectiongiven as two doses of 100mg IV infusion 2 weeks separated.

When glucocorticoids administered as methylprednisolone 100mg IV
Subsequent course based on clinical evaluation must administer every 24 weeks, but not early than every 16 weeks.

LOW GRADE OR FOLLICULAR NON-HODGKINS LYMPHOMA

The drug Dose is 375 mg/m2 as an IV infusion.
Once weeks for 4 or 8 doses administrated for Relapsed treatment
Once weekly for 4 doses administrated for Retreatment for relapsed.
Previously untreated: administer on day 1 of each cycle of chemotherapy, up to 8 doses.

In complete or partial response of patient, start with 8 weeks for maintenance following Mabtas 100mg in combination with chemotherapy completed then administer 8weeks for 12 doses as a single agent.

Once weekly for 4 doses at intervals of 6 months and max of 16 doses for Non – progression (following CVP chemotherapy completion 6 – 8 cycles):
On day 1 each cycle of chemotherapy up to 8 infusions for Diffuse Large B- cell NHL

COMPONENT OF ZEVALIN FOR TREATMENT OF NHL

The dose 250 mg/m2 of Mabtas injection within 4 hours prior to the administration of Indium-111-(In-111-) Zevalin and Yttrium-90- (Y-90-) Zevalin.
7–9 days before to Rituxan and Y-90- Zevalin administrate Rituxan and In-111-Zevalin.

GRANULOMATOSIS POLYANGITIS AND MICROSCOPIC POLYANGITIS

Mabtas injection administer Dose of 375 mg/m2 IV infusion weekly once for 4 weeks.
When Glucocorticoids given with methylprednisolone by dose of 1000 mg IV/ day for 1- 3 days and purse by oral prednisone 1 mg/kg/day are recommended for the treatment of symptoms of serious vacuities.

This drug should initiate within 14 days before or with the starting of Mabtas injection and may continue during and after the 4 week course with treatment of Mabtasinjection drug.
Safety and not established for subsequent infusion.

ADMINISTRTION

Take an amount Mabtasinjection is administer and diluted to final concentration of 1 mg/ml upto 4 mg/ml as infusion (containing either 0.9% Nacl or 5% dextrose in water). Gently Invert the bag and mix the solution. Discard unused drug left in vial.

OVERDOSAGE

If over dose occurs seek immediately to the emergency department or poison control help line. please consult the doctor for further clarification.

Common effects

Fever and chills (flu lik symptoms)

Less common side effects

Weakness; nausea; headache; cough;dyspnea ; pharyngitis

PRECAUTIONS

Allergic condition against Mabtas 100mg or any other medication inform your doctor.
Information about past medical history used which include in prescription, non-prescription, vitamins & supplements, nutritional products just inform the doctor.

Avoid use of Mabtas 100mg if you are pregnant. It will harm the baby unborn, while using Mabtas 100mg use correct birth control to prevent pregnancy and for at least 2 weeks after your treatment ends.
It is unknown whether Mabtas 100mg passes into breast milk, avoid breast-feed while on Mabtas 100mg treatment.
While using Mabtas 100mg do not take any vaccination or immunization without taking advice from doctors.

Drug – drug interaction

Mabtas 100mg drug interaction has limited data is available at present.

Concomitant use with fludarabine or cyclophosphamide have no effects in pharmacokinetics in CLL patients.

Mabtas combination with methotrexate had no effects in pharmacokinetics.

Contraindication

Mabtas combination with methotrexate had no effects in pharmacokinetics.

Category C: In animal studies reproduction describes an adverse effect on the fetus. There are no sufficient and well controlled studies in humans, using in pregnant women benefits by warrant use of the drug.

The drug excretion into human milk is unknown. Because the drug is a higher protein molecule and has no information is available.
Women should not breast feed during Mabtas 100mg treatment and till12 months following last dose.

Store the drug at 2°C – 3°C
Keep away from the children’s
Use the drug before expiry date
Protected from direct sunlight and Do not freeze or shake.
Discard the unused drug by asking the advice from doctor or pharmacist.

If a dose missed then have the drug soon as immediately, if next dose time reach then skip the missed dose and follow the normal schedule. Do not have extra tablet at a same time. Please consult with doctor for further details.

Quick Contact

Prescription upload

PRESCRIPTION

Blueberrypharma.com , a fully licensed and regulated pharmacy medicine, takes all precautions to strictly abide by the laws and regulations set forth in the dispensing of prescription medications. By placing the order for your prescription medicines, you acknowledge and accept the following terms regarding the purchase of any prescription medicines.

Blueberrypharma.com will not dispense any prescription medication without a valid prescription from a licensed physician.

If you are ordering prescription medication(s), you hereby confirm that you will send us a scanned copy of your valid prescription(s) via email, fax, Whatsapp, or by post, and this prescription shall then be subject to the scrutiny of and approval by our qualified Pharmacists.

The drug information provided in the Blueberrypharma.com is for informative purposes only and this Website is not intended to provide diagnosis, treatment or medical advice. We are not liable for any adverse effects or harm to you as a result of your reliance on the information in the Website.

Blueberrypharma.com requires either the User or Customer or the Caregiver to confirm he/she is completely aware of the indications, side effects, drug interactions, effects of missed dose or overdose of the medicines he/she orders from us. It is imperative to seek professional advice from your physician before purchasing or consuming any medicine from Blueberrypharma.com

At Blueberrypharma.com , a Caregiver can order prescription medicines on your behalf.

This information should not be used to decide whether or not to take this Product or any other medicine. Only the healthcare provider has the knowledge and training to decide which medicines are right for a specific patient. This information does not endorse any medicine as safe, effective, or approved for treating any patient or health condition. This is only a brief summary of general information about this Product . It does NOT include all information about the possible uses, directions, warnings, precautions, interactions, adverse effects, or risks that may apply to this product. This information is not specific medical advice and does not replace information you receive from the healthcare provider. You must talk with the healthcare provider for complete information about the risks and benefits of using this product.